Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258058 | 0.84 | FAAH (0.57) | ALDH1A1TDP1MAPTLMNAPTGS2 | |
| SCHEMBL5262130 | 0.83 | FAAH (0.55) | FAAHMAPK1CA1CA2 | |
| SCHEMBL13374821 | 0.83 | HDAC7 (0.56) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL6138050 | 0.82 | USP2 (0.62) | ALDH1A1TDP1MAPTLMNAPTGS2 | |
| Valrocemide SCHEMBL4014030 | 0.81 | HDAC7 (0.54) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL5261317 | 0.80 | CA2 (0.61) | ALDH1A1TDP1MAPTLMNAPTGS2 | |
| SCHEMBL8787755 | 0.80 | USP2 (0.60) | ALDH1A1TDP1MAPTLMNAPTGS2 | |
| SCHEMBL26296395 | 0.79 | HDAC7 (0.62) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL17941558 | 0.79 | DPP7 (0.50) | ALDH1A1TDP1MAPTLMNAPTGS2 | |
| SCHEMBL17941556 | 0.79 | DPP7 (0.50) | ALDH1A1TDP1MAPTLMNAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626707-A4 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | YISSUM RES DEV CO (IL) | 2009-07-01 | — | — | EP | claimed |
| US-20070276045-A1 | Anti-Bacterial Compounds | GIVAUDAN S.A. (CH) | 2007-11-29 | — | — | US | claimed |
| EP-1786381-A1 | ANTI-BACTERIAL COMPOUNDS | Givaudan SA (CH) | 2007-05-23 | — | — | EP | claimed |
| WO-2006026875-A1 | ANTI-BACTERIAL COMPOUNDS | GIVAUDAN SA (CH) | 2006-03-16 | — | — | WO | claimed |
| EP-1626707-A2 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | Teva Pharmaceutical Industries Limited (IL) | 2006-02-22 | — | — | EP | claimed |
| US-20040175423-A1 | Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-09-09 | — | — | US | claimed |
| WO-2004071421-A2 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| EP-1626707-A4 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | YISSUM RES DEV CO (IL) | 2009-07-01 | — | — | EP | disclosed |
| US-20070276045-A1 | Anti-Bacterial Compounds | GIVAUDAN S.A. (CH) | 2007-11-29 | — | — | US | disclosed |
| EP-1786381-A1 | ANTI-BACTERIAL COMPOUNDS | Givaudan SA (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026875-A1 | ANTI-BACTERIAL COMPOUNDS | GIVAUDAN SA (CH) | 2006-03-16 | — | — | WO | disclosed |
| EP-1626707-A2 | SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS | Teva Pharmaceutical Industries Limited (IL) | 2006-02-22 | — | — | EP | disclosed |
| US-20040176463-A1 | Immediate release formulation of n-(2-propylpentanoyl)glycinamide | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-09-09 | — | — | US | disclosed |
| EP-0659174-B1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RES DEV CO (IL) | 1999-02-10 | — | — | EP | disclosed |
| US-5585358-A | ANTIEPILEPTIC AGENTS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; DYSKINESIA; ANTIISCHEMIC AGENTS | YISSUM RESEARCH DEVELOPMENT CORPORATION OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1996-12-17 | — | — | US | disclosed |
| EP-0659174-A4 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS. | YISSUM RES DEV CO (IL) | 1995-09-27 | — | — | EP | disclosed |
| EP-0659174-A1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995001956-A1 | DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-01-19 | — | — | WO | disclosed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | disclosed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176463-A1 | Immediate release formulation of n-(2-propylpentanoyl)glycinamide | CACNA1E, GRIK1, GRIN2D | HDAC7 172/4885HDAC8 144/4885HDAC6 139/4885 |
| US-20070276045-A1 | Anti-Bacterial Compounds | SPOUT1, FASN, CYP8B1 | HDAC7 492/4885HDAC8 1284/4885HDAC6 512/4885 |
| US-20040175423-A1 | Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds | CACNA1E, GRIN2C, GRIN2D | HDAC7 243/4885HDAC8 184/4885HDAC6 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.